Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Jun 30, 2025 | (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | |
|---|---|---|---|---|
| Operating cash flow (direct method) | ||||
| Cash income from operating activities | ||||
| Cash paid | -77.10%-4.11M | -0.64%-2.32M | -103.33%-2.3M | -1.13M |
| Payments to suppliers for goods and services | -77.10%-4.11M | -0.64%-2.32M | -103.33%-2.3M | ---1.13M |
| Direct interest received | 923.57%175.62K | 30.89%17.16K | 3,561.73%13.11K | --358 |
| Operating cash flow | -70.79%-3.93M | -0.47%-2.3M | -102.24%-2.29M | ---1.13M |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | -228.67%-9.62M | 17.04%-2.93M | -149.73%-3.53M | -1.41M |
| Capital expenditure reported | -236.61%-9.25M | 20.89%-2.75M | -148.22%-3.47M | ---1.4M |
| Net PPE purchase and sale | ---- | 189.68%50K | -302.48%-55.76K | ---13.85K |
| Net other investing changes | -62.39%-373.3K | ---229.89K | ---- | ---- |
| Cash from discontinued investing activities | ||||
| Investing cash flow | -228.67%-9.62M | 17.04%-2.93M | -149.73%-3.53M | ---1.41M |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | 306.89%15.22M | -37.76%3.74M | 21.62%6.01M | 4.94M |
| Net common stock issuance | 306.89%15.22M | -37.76%3.74M | 21.62%6.01M | --4.94M |
| Cash from discontinued financing activities | ||||
| Financing cash flow | 306.89%15.22M | -37.76%3.74M | 21.62%6.01M | --4.94M |
| Net cash flow | ||||
| Beginning cash position | -48.28%1.63M | 6.49%3.15M | 425.15%2.96M | --563.86K |
| Current changes in cash | 212.30%1.67M | -874.14%-1.49M | -91.99%192.13K | --2.4M |
| Effect of exchange rate changes | 325.74%79.23K | ---35.1K | ---- | ---- |
| End cash Position | 107.28%3.38M | -48.28%1.63M | 6.49%3.15M | --2.96M |
| Free cash from | -161.03%-13.18M | 13.24%-5.05M | -128.60%-5.82M | ---2.55M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP |